Abstract:Lung cancer is the second most common cancer among both men and women in the United States. The majority of lung cancer cases are classified as non‐small cell lung cancer (NSCLC). Current NSCLC treatments include resection surgery, radiation, and pharmacotherapy which all provide some benefits and have limitations. As a result, lung cancer caused deaths account for about 27% of all cancer deaths in the US. Therefore, new therapeutic agents are highly demanded for NSCLC. MicroRNAs (miRNA or miR) are a class of genome‐derived, small noncoding RNAs (ncRNA) in cells that govern target gene expression through mRNA degradation or translational inhibition. Some miRNAs such as miR‐34a, miR‐124 and let7c are commonly downregulated in NSCLC tissues/cells and target various oncogenes such as CDK6, STAT3, and Ras. Restoring the expression or function of such dysregulated, tumor suppressive miRNAs represents a new strategy for cancer therapy. Aiming at simultaneously introducing multiple miRNAs in NSCLC cells for multi‐targeting, we employed our recently developed ncRNA bioengineering technology to produce a single ncRNA molecule bearing multiple miRNAs. Our data showed that multi‐targeting ncRNA agents were successfully expressed in E. coli . We were able to purify recombinant ncRNAs to a high degree of homogeneity using anion exchange FPLC methods. We further demonstrated that treatment of human NSCLC cells with bioengineered ncRNAs elevated cellular miR‐34a, miR‐124 and let‐7c levels, reduced protein levels of target genes including CDK6, STAT3 and Ras, and consequently inhibited NSCLC cell proliferation. Therefore, using single ncRNA agent for multi‐targeting may be more effective for the treatment of NSCLC. Support or Funding Information This study was supported by grants R01GM133888 and U01CA175315 from NIH. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .

Small Activating RNA Modulation of the G Protein‐Coupled Receptor for Cancer Treatment

RNA Cancer Nanomedicine: Nanotechnology-Mediated RNA Therapy.

Current Advances in Small Activating RNAs for Gene Therapy: Principles, Applications and Challenges.

Tumor-Targeted In Vivo Gene Silencing Via Systemic Delivery Of Crgd-Conjugated Sirna

Single Bioengineered Ncrna Molecule for Dual-Targeting Toward the Control of Non-Small Cell Lung Cancer Patient-Derived Xenograft Tumor Growth.

RNA Activation: Promise As a New Weapon Against Cancer.

Multi-functional Self-Assembled Nanoparticles for Pvegf-Shrna Loading and Anti-Tumor Targeted Therapy.

An Inducible CRISPR-dCas9-Based Transcriptional Repression System for Cancer Therapy

Crab-shaped DNA Tetrahedral Nanomachine for Silencing Undruggable Mrna Targets in Prostate Cancer

Transcriptional Regulation of E-cadherin by Small Activating RNA: A New Double-Stranded RNA.

Nucleus‐specific RNAi Nanoplatform for Targeted Regulation of Nuclear Lncrna Function and Effective Cancer Therapy

Bioengineering of Single Ncrna Molecule for Multi‐targeting Against NSCLC

Regression of Gastric Cancer by Systemic Injection of RNA Nanoparticles Carrying Both Ligand and Sirna

Alkaline Phosphatase-Controllable and Red Light-Activated RNA Modification Approach for Precise Tumor Suppression

High-resolution and programmable RNA-IN and RNA-OUT genetic circuit in living mammalian cells

Promise of Chemokine Network‐targeted Nanoparticles in Combination Nucleic Acid Therapies of Metastatic Cancer

Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin

Double Strand Rna-Guided Endogeneous E-Cadherin Up-Regulation Induces the Apoptosis and Inhibits Proliferation of Breast Carcinoma Cells in Vitro and in Vivo

Abstract 3168: Amphiphilic dendrimer-mediated siRNA delivery for precision regulation of cAMP pathway in cancer cells

Small-molecule targeting of GPCR-independent noncanonical G-protein signaling in cancer

RNA Modulators of Complex Phenotypes in Mammalian Cells.